Schrödinger
IPOPhysics-based Software Platform for Molecular Discovery & Design
Public · New York, United States · Founded 1990 · $195.0M raised
- Headquarters
- New York, New York
- Employees
- 501–1000
- Founded
- 1990
- Business Model
- B2B
- Website
- schrodinger.com
- Total Funding
- $195.0M
- Last Round
- $110.0M Series EMay 2019
- Rounds
- 3
- Type
- Public
About
Schrödinger's computational platform, powered by physics and machine learning, is transforming drug discovery and materials design. With ~900 employees across 12+ offices globally, the company serves biopharmaceutical and industrial customers, academic institutions, and government labs with tools including Maestro, FEP+, and PyMOL for molecular modeling and in silico prediction.
Summary
Schrödinger is an Artificial Intelligence company based in New York, United States, founded in 1990. It has raised $195.0M in total across 3 rounds, most recently a $110.0M Series E round in May 2019. Investors include Qiming VP, GV and Bill & Melinda Gates Foundation.
Tech & App Stack
4 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Feb 2020
Sign up to see all 4 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...

Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.

Alphabet-backed biotechnology company researching biology of aging and developing interventions t...
BridgeBio makes targeted treatments for genetic diseases.
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...